PharmaEssentia: Announcement of the Company's Board of Directors' Resolution to Acquire 100% Equity of Forus Therapeutics Inc.
PharmaEssentia's board of directors resolved on April 9, 2026, to acquire 100% of Forus Therapeutics Inc.'s equity for CAD 50 million. This acquisition aims to strengthen and expand the company's product presence in the Canadian market. The funding will come from own funds or capital raised through overseas depositary receipts issued in 2023.
📋 Article Processing Timeline
- 📰 Published: April 9, 2026 at 09:00
- 🔍 Collected: April 10, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 12:02 (124h 2m after Collected)
1. Name and nature of the subject matter (for preferred shares, the agreed issuance conditions such as dividend rate should also be indicated): 100% equity of Forus Therapeutics Inc.
2. Date of occurrence of the event: 2026/4/9~2026/4/9
3. Date of board resolution: April 9, 2026 (ROC calendar)
4. Other approval dates: Not applicable
5. Transaction quantity, unit price, and total transaction amount: Total transaction amount: CAD 50 million.
6. Counterparty and its relationship with the company (if the counterparty is a natural person and not a related party of the company, their name may be omitted): Counterparty: FORUS Therapeutics Inc. Relationship with the company: None.
7. If the counterparty is a related party, the reason for selecting the related party as the transaction counterparty, the previous owner, the relationship between the previous owner, the company, and the counterparty, the previous transfer date, and transfer amount should also be disclosed: Not applicable.
8. If the subject matter of the transaction has been owned by a related party of the company within the past five years, the related party's acquisition and disposal dates, prices, and relationship with the company at the time of the transaction should also be disclosed: Not applicable.
9. Matters related to the disposal of claims (including the type of collateral attached to the claims, and if the disposed claims belong to related party claims, the name of the related party and the book value of the related party's claims disposed of this time should also be disclosed): Not applicable.
10. Disposal gains (or losses) (not applicable for acquisition of securities) (if deferred, explain the recognition status in a table): Not applicable.
11. Delivery or payment terms (including payment period and amount), contract restrictions, and other important agreements: Handled according to contract terms.
12. Method of determining this transaction, reference basis for price determination, and decision-making unit: The transaction price was determined with reference to the valuation report issued by an independent expert and approved by the Company's board of directors.
13. Net asset value per share of the acquired or disposed securities company: Not applicable.
14. As of now, the cumulative quantity, amount, shareholding ratio, and restricted rights (e.g., pledge status) of this transaction's securities (including this transaction): Amount: CAD 50 million. Shareholding ratio: 100%. Restricted rights: None.
15. As of now, the proportion of investments in securities listed in Article 3 of the "Regulations Governing the Acquisition and Disposal of Assets by Public Companies" (including this transaction) to the total assets and equity attributable to owners of the parent company in the company's latest financial statements, and the working capital amount in the latest financial statements (Note 2): Proportion of total assets: 3.34%. Proportion of equity attributable to owners of the parent company: 3.65%. Working capital amount: NT$17,434,969 thousand.
16. Broker and brokerage fees: Not applicable.
17. Specific purpose or use of acquisition or disposal: To consolidate and expand the Company's product market in Canada.
18. Opinions of dissenting directors on this transaction: None.
19. Is this transaction a related party transaction: No.
20. Date of approval by supervisors or audit committee: April 9, 2026 (ROC calendar).
21. Does the accountant issue an unreasonable opinion on this transaction: No.
22. Name of accounting firm: Yongqin Accounting Firm.
23. Name of accountant: Chang Ying-Yen.
24. Accountant's practice certificate number: Taipei City Certificate No. 3251.
25. Does it involve a change in business model: No.
26. Explanation of business model change: Not applicable.
27. Transaction status with the counterparty in the past year and expected next year: Not applicable.
28. Source of funds: Own funds or funds raised from overseas depositary receipts issued by the Company in 2023.
29. Date of previous major announcement on the same event: Not applicable.
30. Other matters to be specified: None.
2. Date of occurrence of the event: 2026/4/9~2026/4/9
3. Date of board resolution: April 9, 2026 (ROC calendar)
4. Other approval dates: Not applicable
5. Transaction quantity, unit price, and total transaction amount: Total transaction amount: CAD 50 million.
6. Counterparty and its relationship with the company (if the counterparty is a natural person and not a related party of the company, their name may be omitted): Counterparty: FORUS Therapeutics Inc. Relationship with the company: None.
7. If the counterparty is a related party, the reason for selecting the related party as the transaction counterparty, the previous owner, the relationship between the previous owner, the company, and the counterparty, the previous transfer date, and transfer amount should also be disclosed: Not applicable.
8. If the subject matter of the transaction has been owned by a related party of the company within the past five years, the related party's acquisition and disposal dates, prices, and relationship with the company at the time of the transaction should also be disclosed: Not applicable.
9. Matters related to the disposal of claims (including the type of collateral attached to the claims, and if the disposed claims belong to related party claims, the name of the related party and the book value of the related party's claims disposed of this time should also be disclosed): Not applicable.
10. Disposal gains (or losses) (not applicable for acquisition of securities) (if deferred, explain the recognition status in a table): Not applicable.
11. Delivery or payment terms (including payment period and amount), contract restrictions, and other important agreements: Handled according to contract terms.
12. Method of determining this transaction, reference basis for price determination, and decision-making unit: The transaction price was determined with reference to the valuation report issued by an independent expert and approved by the Company's board of directors.
13. Net asset value per share of the acquired or disposed securities company: Not applicable.
14. As of now, the cumulative quantity, amount, shareholding ratio, and restricted rights (e.g., pledge status) of this transaction's securities (including this transaction): Amount: CAD 50 million. Shareholding ratio: 100%. Restricted rights: None.
15. As of now, the proportion of investments in securities listed in Article 3 of the "Regulations Governing the Acquisition and Disposal of Assets by Public Companies" (including this transaction) to the total assets and equity attributable to owners of the parent company in the company's latest financial statements, and the working capital amount in the latest financial statements (Note 2): Proportion of total assets: 3.34%. Proportion of equity attributable to owners of the parent company: 3.65%. Working capital amount: NT$17,434,969 thousand.
16. Broker and brokerage fees: Not applicable.
17. Specific purpose or use of acquisition or disposal: To consolidate and expand the Company's product market in Canada.
18. Opinions of dissenting directors on this transaction: None.
19. Is this transaction a related party transaction: No.
20. Date of approval by supervisors or audit committee: April 9, 2026 (ROC calendar).
21. Does the accountant issue an unreasonable opinion on this transaction: No.
22. Name of accounting firm: Yongqin Accounting Firm.
23. Name of accountant: Chang Ying-Yen.
24. Accountant's practice certificate number: Taipei City Certificate No. 3251.
25. Does it involve a change in business model: No.
26. Explanation of business model change: Not applicable.
27. Transaction status with the counterparty in the past year and expected next year: Not applicable.
28. Source of funds: Own funds or funds raised from overseas depositary receipts issued by the Company in 2023.
29. Date of previous major announcement on the same event: Not applicable.
30. Other matters to be specified: None.